QP 07 - Palliative 2: The Next Generation in Palliation: From MR-guided SABR to Patient Selection and Everything in Between

Moderator(s)

• 

  Lindsay Puckett, MD

  Medical College of Wisconsin
  Milwaukee, WI, United States
• 

  Anish Butala, MD

  University of Pennsylvania
  Philadelphia, Pennsylvania

Presentations:

• 8:00 AM – 8:05 AM ET

  Introduction
• 8:05 AM – 8:10 AM ET

  ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer
  

  Presenter: Mylin Torres, MD, FASTRO – Emory University
• 8:10 AM – 8:15 AM ET

  Phase 2 Trial of Stereotactic MR-Guided Adaptive Radiation Therapy in One Fraction (SMART ONE)
  

  Presenter: Michael Chuong, MD – Miami Cancer Institute
• 8:15 AM – 8:20 AM ET

  Final Report of a Phase I/II Study of BMS-986156 (Glucocorticoid-Induced TNFR-Related Gene [GITR] Agonist) with Ipilimumab or Nivolumab with/without Stereotactic Ablative Radiotherapy in Patients with
  

  Presenter: Xinyan Xu, MD – MD Anderson Cancer Center
• 8:20 AM – 8:25 AM ET

  Identifying Patients with Bone Metastases at Highest Risk of Skeletal-Related Events and Understanding Underuse of Bone Modifying Agents: A Retrospective Analysis
  

  Presenter: Lakshmi Rekha Narra, MD – Rutgers Cancer Institute of New Jersey
• 8:25 AM – 8:30 AM ET

  Development of Nomograms to Predict Polymetastatic Progression Free Survival and Overall Survival in Patients Treated with Stereotactic Ablative Radiotherapy for Oligometastatic or Oligoprogressive Ca
  

  Presenter: Subhadip Das, MD – BC Cancer Surrey and University of British Columbia
• 8:30 AM – 8:35 AM ET

  Progress in Shortening Treatment Courses for Bone Metastases in a Statewide Quality Consortium
  

  Presenter: Luke Higgins, MD – University of Michigan
• 8:35 AM – 8:55 AM ET

  Questions and Answers
• 8:55 AM – 9:00 AM ET

  Closing